P. Chan

发表

Prostaglandins, prostacyclin, and thromboxane in cardiovascular diseases

P. Chan, P. Cervoni, 1986 .

Chromate Inhibition, in Erythrocytes, of Chemically Stimulated Increases in Glucose Oxidation via the Hexosemonophosphate Pathway (HMP)∗

M. Chandler, L. Beck, P. Chan, 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.

H. Mazandarani, J. Coupet, P. Chan, 1999, Bioorganic & medicinal chemistry letters.

Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.

David K. Williams, R. Steffan, E. Trybulski, 2006, Bioorganic & medicinal chemistry letters.

Antihypertensive activity and effects on blood flow of CL 115,999 (5‐lodo‐5,6‐dihydro‐15‐deoxy‐16‐hydroxy‐16‐vinyl‐prostacyclin methyl ester), a new potent orally and transdermally long‐acting prostacyclin analog

P. Chan, P. Cervoni, M. A. Ronsberg, 1989 .

Current concepts and animal models of sudden cardiac death for drug development

P. Chan, P. Cervoni, 1990 .

VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.

J. Taylor, Joseph R. Taylor, J. Dusza, 1998, Advances in experimental medicine and biology.

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.

M. Reich, J. Dusza, H. Mazandarani, 1998, Journal of medicinal chemistry.

The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.

J. Dusza, H. Mazandarani, J. Coupet, 2000, Bioorganic & medicinal chemistry letters.

(4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.

A. Failli, J. Coupet, P. Chan, 2005, Bioorganic & medicinal chemistry letters.

CL 115,347 (DHV-PGE2 ME): a new orally and topically active prostaglandin antihypertensive agent.

P. Chan, P. Cervoni, F. Lai, 1983, Federation proceedings.

Recent Advances in the Discovery and Development of Vasopressin Antagonists: Peptide and Nonpeptide Vta and V2 Receptor Antagonists

P. Chan, J. D. Albright, 1997, Current Pharmaceutical Design.

The synthesis of 2,3-dihydro-4(1H)-quinazolinone angiotensin II receptor antagonists

J. Levin, A. Katocs, P. Chan, 1994 .

Quinazolinylformamidines and quinazolinediylbisformamidines as antihypertensive agents.

S. Lang, J. Warren, P. Chan, 1978, Journal of pharmaceutical sciences.

6-SUBSTITUTED QUINAZOLINONE ANGIOTENSIN II RECEPTOR ANTAGONISTS

J. Levin, J. Coupet, P. Chan, 1994 .

Thromboxane synthetase inhibitors and antihypertensive agents. 4. N-[(1H-imidazol-1-yl)alkyl] derivatives of quinazoline-2,4(1H,3H)-diones, quinazolin-4(3H)-ones, and 1,2,3-benzotriazin-4(3H)-ones.

W. B. Wright, P. Chan, A. S. Tomcufcik, 1987, Journal of medicinal chemistry.

Thromboxane Synthetase Inhibitors and Antihypertensive Agents.

W. B. Wright, P. Chan, A. S. Tomcufcik, 1986 .

6-ISOXAZOLINYL AND ISOXAZOLIDINYL SUBSTITUTED QUINAZOLINONES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS

J. Levin, J. Coupet, P. Chan, 1994 .

Studies on the mechanism of the enhancement of the antihypertensive activity of captopril by a diuretic in spontaneously hypertensive rats.

T. Tanikella, P. Chan, P. Cervoni, 1982, Clinical and experimental hypertension. Part A, Theory and practice.

Aromatic amino acid hydroxylase inhibitors. 1. Halogenated phenylalanines.

R. Counsell, P. Chan, P. Weinhold, 1970, Journal of medicinal chemistry.

DIFFERENCES IN DIHYDROERGOTAMINE ANTAGONISM OF GLUCOSE RELEASE BY CATECHOLAMINES, GLUCAGON AND ADENOSINE 3′,5′‐MONOPHOSPHATE IN RABBIT LIVER SLICES

P. Chan, E. Muhlbachova, S. Ellis, 1978, British journal of pharmacology.

4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.

H. Mazandarani, J. Coupet, P. Chan, 1999, Bioorganic & medicinal chemistry letters.

Laser-induced injury in mouse ear arteries as a model for in vivo studies of arterial thrombosis

P. Chan, L. Ellenbogen, 1974 .

Sequential method for combined screening antihypertensive and diuretic agents in the same spontaneously hypertensive rat (SHR).

P. Chan, D. Poorvin, 1979, Clinical and experimental hypertension.

5-(1-piperazinyl)-1H-1,2,4-triazol-3-amines as antihypertensive agents.

P. Chan, A. S. Tomcufcik, W. E. Meyer, 1989, Journal of medicinal chemistry.

Studies on the mechanism of the synergistic antihypertensive activity of captopril and hydrochlorothiazide following acute administration in spontaneously hypertensive rats.

P. Chan, P. Cervoni, M. A. Ronsberg, 1982, Clinical and experimental hypertension. Part A, Theory and practice.

Prostaglandins and congeners, 29. (16RS)-(+/-)-15-Deoxy-16-hydroxy-16-vinyl-prostaglandin E2, an orally and transdermally active hypotensive agent of prolonged duration.

M. B. Floyd, F. Dessy, C. Grudzinskas, 1982, Journal of medicinal chemistry.

Antiarrhythmic agents inhibit the in vitro formation of thromboxane (TX) in platelets from spontaneously hypertensive rats (SHR).

J. Lucas, P. Chan, P. Cervoni, 1987, Prostaglandins, leukotrienes, and medicine.

Quantitative studies of glucose release from rabbit liver slices induced by catecholamines and their antagonism by propranolol and phentolamine.

P. Chan, S. Ellis, E. Mühlbachová, 1972, The Journal of pharmacology and experimental therapeutics.

Thromboxane synthetase inhibitors and antihypertensive agents. 1. N-[(1H-imidazol-1-yl)alkyl]aryl amides and N-[(1H-1,2,4-triazol-1-yl)alkyl]aryl amides.

W. B. Wright, J. Lucas, P. Chan, 1986, Journal of medicinal chemistry.

1-Benzylimidazole, a thromboxane synthetase inhibitor acutely lowers blood pressure mainly by alpha-adrenoceptor blockade in spontaneously hypertensive rats (SHR).

J. Lucas, P. Chan, P. Cervoni, 1983, Prostaglandins, leukotrienes, and medicine.

Cutaneous erythema and blood pressure lowering effects of topically applied 16-vinylprostaglandins.

F. Dessy, P. Chan, P. Cervoni, 1982, Prostaglandins.